https://www.washingt...-200000-a-year/
rct
What a country
Started by
rct
, Oct 20 2016 03:43 PM
6 replies to this topic
#2
Melanie
-
- Members
-
- 219 posts
Advanced Member
- LocationArizona
Posted 20 October 2016 - 11:12 PM
Wow...it's just crazy and way out of hand!
Dx - 05/2011; PCR: 15.04; Fish: 87% Slow responder due to pancytopenia. Current - Bosulif - Nov: 2012, Mar 2016 lowered to 300 mg. 07/16 back to 400 mg. Clinical trial drug, Promacta, Feb 2013, for low Platelets.
CyCR - Aug 2014, Positive for 1 chromosome Sep 2015. PCR: 12.77 in Oct, 2012 to 0.04 (MDA) in Mar, 2016. 4/2016 - 0.126 (Local lab (IS); 05/2016 - 0.195 (local); 6/2016 - 0.07 (MDA); 7/2016 - 0.03 (local) 9/13/2016 - 0.16 (MDA); 9/26/2016 - 0.31 (MDA); 11/2016 - 0.012 (local); 01/2017 - 0.24 (MDA); 04/2017 - 0.09 (MDA); Cytogenetics show der(1:7)(q10;p10)7 chromosome mutation. Repeat of Sep 2015. PCR - 6/2017- 0.035 (local); 10/2017- 0.02 (MDA)
CyCR - Aug 2014, Positive for 1 chromosome Sep 2015. PCR: 12.77 in Oct, 2012 to 0.04 (MDA) in Mar, 2016. 4/2016 - 0.126 (Local lab (IS); 05/2016 - 0.195 (local); 6/2016 - 0.07 (MDA); 7/2016 - 0.03 (local) 9/13/2016 - 0.16 (MDA); 9/26/2016 - 0.31 (MDA); 11/2016 - 0.012 (local); 01/2017 - 0.24 (MDA); 04/2017 - 0.09 (MDA); Cytogenetics show der(1:7)(q10;p10)7 chromosome mutation. Repeat of Sep 2015. PCR - 6/2017- 0.035 (local); 10/2017- 0.02 (MDA)
#3
Billie Murawski
-
- Members
-
- 711 posts
Advanced Member
- LocationErie,Pa
Posted 20 October 2016 - 11:47 PM
It's so frustrating reading and learning and hearing all this stuff and not being able to do a damn thing about it. Yeah I vote but as we learned a few years back our vote doesn't count! Where is the John Kansius machine it was approved for human trials and the first patients were supposed to be Pancreatic Cancer Patients, Why do I have a cousin fighting pancreatic cancer right now, and my neighbor a wonderful man who died at age 45 from pancreatic cancer!!!!! And if we didn't have TKIs we wouldn't have a chance at life and TKIs haven't been around that long.
And why is there a damn piss ant crawling across my screen in October? nuff said Billie
#4
chriskuo
-
- Members
-
- 367 posts
Advanced Member
Posted 21 October 2016 - 12:47 AM
The problem is Bernie Sanders is considered a wild-eyed socialist by most of Congress. It will take a coalition of moderate Democrats and Republicans to fix this problem. We'll see if anybody gets the hint.
#5
r06ue1
-
- Members
-
- 426 posts
Advanced Member
- LocationEarth, Solar System, Milky Way, Local Group, Virgo Supercluster, Laniakea
Posted 21 October 2016 - 05:50 AM
lol, price gouging the insurance companies (and the consumers that pay for private insurance in the end), plain and simple.
08/2015 Initial PCR: 66.392%
12/2015 PCR: 1.573%
03/2016 PCR: 0.153%
06/2016 PCR: 0.070%
09/2016 PCR: 0.052%
12/2016 PCR: 0.036%
03/2017 PCR: 0.029%
06/2017 PCR: 0.028%
09/2017 PCR: 0.025%
12/2017 PCR: 0.018%
Taking Imatinib 400 mg
#6
r06ue1
-
- Members
-
- 426 posts
Advanced Member
- LocationEarth, Solar System, Milky Way, Local Group, Virgo Supercluster, Laniakea
Posted 21 October 2016 - 06:36 AM
08/2015 Initial PCR: 66.392%
12/2015 PCR: 1.573%
03/2016 PCR: 0.153%
06/2016 PCR: 0.070%
09/2016 PCR: 0.052%
12/2016 PCR: 0.036%
03/2017 PCR: 0.029%
06/2017 PCR: 0.028%
09/2017 PCR: 0.025%
12/2017 PCR: 0.018%
Taking Imatinib 400 mg
#7
Red Cross Kirk
-
- Members
-
- 173 posts
Advanced Member
- LocationOregon
Posted 21 October 2016 - 09:46 AM
This section caught my eye:
"Herceptin had already been developed, but Genentech executives didn't care. Testing to see if it worked risked wasting money and these executives were becoming very risk averse. Genentech executives weren't alone in their risk aversion either. From 1995-1997 Novartis executives tried equally hard to kill Gleevec- another miracle drug that suppresses a deadly form of leukemia indefinitely-because they feared that the trials needed to clear Gleevec would cost too much (Page 436).
Fortunately, both Gleevec and Herceptin got the funding they needed and are now providing billions of dollars in revenue to the pharmaceutical companies that tried to kill them. They were among the last new ideas to get funding from the drug companies though. By the time Gleevec came on the market in 2000 the door had mostly shut on novel pharmaceutical research."
Kirk
9/25/2012 p210 transcript 118.7% IS @ Dx, begin Gleevec 400mg/day
12/2012 3.59% & bone marrow biopsy - no residual myeloproliferative features but detected 1/20 metaphases containing the Philadelphia chromosome
2013 0.914%, 0.434%, 0.412%
10/2013 0.360% & bone marrow biopsy - normal male karyotype with no evidence of a clonal cytogenetic abnormaltiy
2014 0.174%, 0.088%, 0.064%
2015 0.049%, decrease to Gleevec 200mg/day, 0.035%, 0.061%, 0.028%
2016 0.041%, 0.039%, 0.025%
2017 0.029%, 0.039%, switched to generic imatinib 200mg/day, 0.070%, 0.088%
2018 0.233%
1 user(s) are reading this topic
0 members, 1 guests, 0 anonymous users
